RDHL   $0.3441  -1.27% Market Closed

Redhill Biopharma Ltd
Last Events:

2023-08-09 Trend pattern changed from канал to расходящийся клин с наклоном вниз.

2023-08-06 Trend pattern changed from расходящийся клин с наклоном вниз to канал.

2023-08-04 Signal in Stochastic changed from bullish reversal to bearish recovery. The stochastic indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: main and signal line crossing.

2023-08-02 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-08-02 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-07-30 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-07-29 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-07-23 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.


Current temperature: 0.25
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 1.57
Target: 40.00
High with 49% probability: 5.87
Analyst Recommendations:
Number of estimates 1
Target Price Mean 40.00
Mean unverified/preliminary 40.00 / 40.00
Target Price Low / High 40.00 / 40.00
Median / STD DEV 40.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell None
macd Sell None None
stoch Sell None None
ma20 Sell Sell Sell
ma50 Sell None None
ma100 Sell Sell Sell
Candlestick PatternNov. 13, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US7574682024
ceo Mr. Dror Ben-Asher
Website https://www.redhillbio.com
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.